Relmada Therapeutics has a 12-month low of $0.24 and a 12-month high of $6.38. The firm’s fifty day moving average is $0.35 and its 200 day moving average is $1.82.

CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone ...

Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid developed for treating Tourette syndrome (TS) and related compulsive disorders, from Asarina Pharma ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled ...

(RTTNews) - Relmada Therapeutics, Inc. (RLMD), a clinical-stage biotechnology company, on Thursday announced the acquisition of Sepranolone, a Phase 2b-ready neurosteroid, from Asarina Pharma AB.

Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder ValueCORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: ...

In a challenging year for Relmada Therapeutics (NASDAQ:RLMD), the company's stock has plummeted to a 52-week low, trading at ...